Table 3. Clinicopathological characteristics according to AR and FOXA1 mRNA status in ER-positive breast cancer patients from the METABRIC dataset.
| Factor | AR-high/FOXA1-high(n, %) | AR-high/FOXA1-low(n, %) | AR-low/FOXA1-high(n, %) | AR-low/FOXA1-low(n, %) | p-value |
|---|---|---|---|---|---|
| Age (yrs) | |||||
| ≤ 50 | 172 (14.7) | 11 (11.3) | 33 (22.3) | 14 (19.4) | 0.048 |
| > 50 | 996 (85.3) | 86 (88.7) | 115 (77.7) | 58 (80.6) | |
| TNM stage | |||||
| Stage I | 336 (31.5) | 28 (29.8) | 60 (40.8) | 26 (36.1) | 0.085 |
| Stage II | 685 (59.0) | 54 (57.4) | 78 (53.1) | 35 (48.6) | |
| Stage III | 110 (9.5) | 12 (12.8) | 9 (6.1) | 11 (15.3) | |
| Histologic grade | |||||
| I/II | 701 (62.8) | 44 (47.3) | 79 (54.5) | 34 (47.2) | 0.001 |
| III | 415 (37.2) | 49 (52.7) | 66 (45.5) | 38 (52.8) | |
| PR* | |||||
| Positive | 823 (70.5) | 48 (49.5) | 81 (54.7) | 15 (20.8) | < 0.001 |
| Negative | 345 (29.5) | 49 (50.5) | 67 (45.3) | 57 (79.2) | |
| HER2* | |||||
| Negative | 1,081 (92.6) | 86 (88.7) | 135 (91.2) | 68 (94.4) | 0.457 |
| Positive | 87 (7.4) | 11 (11.3) | 13 (8.8) | 4 (5.6) | |
| PAM50 subtype | |||||
| Luminal A | 613 (52.7) | 19 (20.0) | 56 (37.8) | 4 (5.6) | < 0.001 |
| Luminal B | 373 (32.0) | 20 (21.1) | 62 (41.9) | 6 (8.3) | |
| HER2 | 74 (6.4) | 15 (15.8) | 15 (10.1) | 9 (12.5) | |
| Basal | 9 (0.8) | 14 (14.7) | 5 (3.4) | 30 (41.7) | |
| Normal | 95 (8.2) | 27 (28.4) | 10 (6.8) | 23 (31.9) | |
| Type of surgery | |||||
| BCS | 459 (39.5) | 38 (40.9) | 70 (47.6) | 30 (42.9) | 0.296 |
| TM | 702 (60.5) | 55 (59.1) | 77 (52.4) | 40 (57.1) | |
| Radiotherapy | |||||
| Not done | 510 (43.7) | 32 (33.0) | 57 (38.5) | 26 (36.1) | 0.097 |
| Done | 658 (56.3) | 65 (67.0) | 91 (61.5) | 46 (63.9) | |
| Chemotherapy | |||||
| Not done | 1,073 (91.9) | 92 (94.8) | 128 (86.5) | 55 (76.4) | < 0.001 |
| Done | 95 (8.1) | 5 (5.2) | 20 (13.5) | 17 (23.6) | |
| Hormone therapy | |||||
| Not done | 311 (26.6) | 24 (24.7) | 37 (25.0) | 17 (23.6) | 0.902 |
| Done | 857 (73.4) | 73 (75.3) | 111 (75.0) | 55 (76.4) |
*Positive criteria of PR and HER2 were defined as expression status in the METABRIC dataset.